Immunoprotein Diagnostic Testing Market

SKU: DM2306 | Last Updated On: Sep 13 2022 | Available Formats

> Immunoprotein Diagnostic Testing Market Expected to reach a high CAGR of 7.9% by 2029: DataM Intelligence

Immunoprotein Diagnostic Testing Market is segmented By Test Type (Immunoglobulin Diagnostic Tests, C-Reactive Protein (CRP) Diagnostic Tests, Complement System Proteins Diagnostic Tests, Free Light Chain Diagnostic Tests, Haptoglobin Diagnostic Tests, Prealbumin Diagnostic Tests, Others), By Application (Autoimmune Disease Testing, Infectious Disease Testing, Oncology Testing, Allergy Testing, Toxicology Testing), By Technology (Enzyme Based Immunoassay, Radioimmunoassay, Immunoprotein Electrophoresis, Chemiluminescence Assay, Immunofluorescence Assay, Immunoturbidity Assay, Others), By End-User (Hospital and clinics, Diagnostic laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Immunoprotein Diagnostic Testing Market size was valued US$ 11,480.26 million in 2021 and is estimated to reach US$ 20,938.71 million by 2029, growing at a CAGR of 7.9% during the forecast period (2022-2029).

Immunoprotein Diagnostic Testing Market Scope

Metrics

Details

Market CAGR

7.9%

Segments Covered

By Test Type, By Application, By Technology, By End-Users, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into Market, Get Our Sample Brochure

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze certain proteins such as immunoglobulin and pre-albumin. With continuous development in technologies, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Market Dynamics

The global immunoprotein diagnostic testing market is growing owing to the rising prevalence of obesity, rheumatoid arthritis, cancer, type 2 diabetes, infectious diseases, and cardiovascular disease.

Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer is expected to drive market growth.

According to the World Health Organization (WHO), it has been projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths are due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The number of people in the developing world with diabetes will increase by more than 2.5-fold, from 84 million in 1995 to 228 million in 2025. On a global basis, 60% of the burden of chronic diseases will occur in developing countries. Indeed, cardiovascular diseases are even now more numerous in India and China than in all the economically developed countries in the world put together. As for overweight and obesity, not only has the current prevalence already reached unprecedented levels, but the rate at which it is annually increasing in most developing regions is substantial. The public health implications of this phenomenon are staggering and are already becoming apparent. Hence, the rising prevalence of chronic diseases has raised the demand for rapid diagnosis.

The rising geriatric population coupled with an all-time high incidence of chronic diseases has given an impetus to the global market's growth for immunoprotein diagnostic testing. Moreover, the upswing in demand for immunoprotein diagnostic testing can also be attributed to the prevalence of infectious diseases worldwide. Unhygienic living conditions, especially in underdeveloped regions, have also led to diseases and infections. This has brought the global market for immunoprotein diagnostic testing under the spotlight of attention.

High cost of diagnostic tests is expected to hamper the market growth.

The regulatory framework is very complex and doesn’t approve many immunoprotein diagnostic tests easily and high cost of some diagnostic tests can hamper the growth of the market.

Industry Analysis

The global Immunoprotein Diagnostic Testing market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Enzyme based immunoassay segment is expected to hold the largest market share in global immunoprotein diagnostic testing market

Based on technology, the immunoprotein diagnostic testing market is segmented into enzyme-based immunoassay, radioimmunoassay, immunoprotein electrophoresis, chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, and others. Among these, enzyme-based immunoassay (EIA) accounted for the largest market share. EIA has used a diagnostic and quality tool in several laboratories and companies. Also, some of the major companies are developing new products with EIA technology. For instance, Abcam offers Human Complement C3 ELISA Kit for diagnosis.

On the other hand, chemiluminescence assay is expected to grow at the highest growth rate during the forecast period, owing to its features such as high sensitivity and specificity, strong ability to detect antigens in human serum & plasma samples. Chemiluminescence assay is an important tool for the instant diagnosis of several diseases and is ascertained to be more accurate than fluorescence-based detection of labeled probes. On November 6th, 2019, ALPCO has launched its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Based on application, the immunoprotein diagnostic testing is be segmented into autoimmune disease testing, infectious disease testing, oncology testing, allergy testing, toxicology testing, and endocrine testing. Among these, oncology testing accounted for the largest market share, with rising demand over the forecast period. The presence of various diagnostic methods, such as Epidermal Growth Factor Receptor (EGFR) testing, helps detect mutations in the EFGR gene, which occurs in patients with non-small cell lung cancer, and this helps in treatment planning. In March 2019, NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, launched the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with a triple-negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple-negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy TECENTRIQ (atezolizumab) used in combination with chemotherapy. TECENTRIQ is the first immunotherapy approved specifically for breast cancer.

Geographical Analysis

North America region holds the largest market share in the global immunoprotein diagnostic testing market

North America is dominating the global immunoprotein diagnostic testing market accounted for the largest market share, owing to rising incidences of chronic diseases, rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year. By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. They account for 81% of hospital admissions, 91% of all prescriptions filled, and 76% of all physician visit. In another instance, the American Cancer Society projected around 1,806,590 new cancer cases and 606,520 cancer deaths in the United States in the year 2020. Because of such a projection, accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

Competitive Landscape

Some of the major players in the immunoprotein diagnostic testing market include F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics, among others.

The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations contributing to the Immunoprotein Diagnostic Testing market globally. For instance,

  • In July 2019, the U.S. Food and Drug Administration (FDA) cleared for marketing four previously cleared tests with new indications to aid in diagnosing Lyme disease. The tests cleared are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.

Global Immunoprotein Diagnostic Testing Market – Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Afinion 2: It is an analyser that is a compact, rapid and can perform multi-assay which gives important near patient diagnosis or testing at the point-of-care.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global immunoprotein diagnostic testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Predictive Diagnostics Market

In-Vitro Diagnostics Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest